Oral TYK2 Inhibition in Atopic Dermatitis - Poll - MDSpire

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.

  • By

  • Kathryn Wighton

  • February 5, 2026

  • 4 min

Share

Original Source(s)

Oral TYK2 Inhibition in Atopic Dermatitis

  • by Kathryn Wighton

  • February 5, 2026

Related Content

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.

Pediatric Dermatology Clinic now accepting referrals for complex cases

This program provides subspecialty expertise in the diagnosis and management of complex pediatric dermatologic diseases.

  • May 14, 2026

  • 1 min
Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations